Abstract Background Neoantigen-targeting therapies including personalized vaccines have shown promise in the treatment of cancers. particularly when used in combination with checkpoint blockade therapy. At least 100 clinical trials involving these therapies have been initiated globally. Accurate identification and prioritization of neoantigens is crucial for designing these trials. https://nvmeclothingers.shop/product-category/prom-dress/